SNTI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SNTI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of Sep24, Senti Biosciences's earnings power value is $-5.29. *
* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.
Margin of Safety is N/A.
The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future. Assumption: Current profitability is sustainable.
The historical data trend for Senti Biosciences's Earnings Power Value (EPV) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Senti Biosciences Annual Data | |||||||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | |||||
Earnings Power Value (EPV) | - | - | - | - |
Senti Biosciences Quarterly Data | |||||||||||||||
Dec20 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Earnings Power Value (EPV) | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
- | - | - | - | - |
For the Biotechnology subindustry, Senti Biosciences's Earnings Power Value (EPV), along with its competitors' market caps and Earnings Power Value (EPV) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Senti Biosciences's Earnings Power Value (EPV) distribution charts can be found below:
* The bar in red indicates where Senti Biosciences's Earnings Power Value (EPV) falls into.
Earnings Power Value also known as just Earnings Power is a valuation technique popularised by Bruce Greenwald, an authority on value investing at Columbia University. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future.
The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. This valuation tool excludes the potential growth that a company may have so that needs to be looked at separately. Since future growth is excluded from the analysis, only the maintenance capital expenditures are subtracted from after-tax EBIT (earnings before interest and taxes) and growth capex is ignored.
Senti Biosciences (NAS:SNTI) Earnings Power Value (EPV) Explanation
Assumption: Current profitability is sustainable.
Earnings power value (EPV) uses a very basic equation which assumes no growth, although it does rely on an assumption about the cost of capital as well as the fact that current earnings are sustainable. It also involves several adjustments to clean up the underlying Earnings figures.
Be Aware
Though using today's earnings in calculating Earnings Power Value, GuruFocus is normalizing these earnings to the business cycle. This eliminates the effects on profitability of valuing the firm at different points in the business cycle. This means that we are considering the average earnings over 5 years.
Thank you for viewing the detailed overview of Senti Biosciences's Earnings Power Value (EPV) provided by GuruFocus.com. Please click on the following links to see related term pages.
Timothy K Lu | director, officer: CEO and President | SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080 |
Kanya Rajangam | officer: Chief Medical & Devt. Officer | C/O SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080 |
Aktiengesellschaft Bayer | 10 percent owner | BAYERWERK, GEBAEUDE W11, KAISER-WILHELM-ALLEE, LEVERKUSEN 2M D-51368 |
Susan D Berland | director | C/O SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080 |
James J. Collins | director | C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
Bayer World Investments B.v. | 10 percent owner | ENERGIEWEG 1, MIJDRECHT P7 3641 |
Deborah Knobelman | officer: Chief Financial Officer | C/O SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080 |
Herberts Curt A. Iii | officer: Chief Operating Officer | 501 CANAL BLVD., POINT RICHMOND TECH CENTER, RICHMOND CA 94804 |
Brenda Cooperstone | director | C/O SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080 |
Philip J Lee | officer: Chief Technology Officer | C/O SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080 |
Edward T Mathers | director | C/O MEDIMMUNE, INC., ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878 |
Mohamad Makhzoumi | 10 percent owner | 2855 SAND HILL ROAD, MENLO PARK CA 94025 |
Nea 15 Gp, Llc | 10 percent owner | 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093 |
Nea Partners 15, L.p. | 10 percent owner | 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093 |
New Enterprise Associates 15, L.p. | 10 percent owner | 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093 |
From GuruFocus
By Marketwired • 08-13-2024
By GuruFocus News • 02-15-2025
By Marketwired • 12-16-2024
By Marketwired • 11-14-2024
By Marketwired • 05-13-2024
By GuruFocus Research • 02-09-2024
By GuruFocus News • 11-14-2024
By GuruFocus Research • 02-09-2024
By Marketwired • 11-06-2023
By Marketwired • 09-05-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.